BioMarin Pharmaceuticals BMRN Unrealized Gain (Loss), Foreign Currency Transaction, before Tax
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossUnrealized.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's unrealized gain (loss), foreign currency transaction, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's unrealized gain (loss), foreign currency transaction, before tax?
- BioMarin Pharmaceuticals (BMRN) reported unrealized gain (loss), foreign currency transaction, before tax of -$6.71M in Q1 2026.
- How has BioMarin Pharmaceuticals's unrealized gain (loss), foreign currency transaction, before tax changed year-over-year?
- BioMarin Pharmaceuticals's unrealized gain (loss), foreign currency transaction, before tax decreased by 166.9% year-over-year, from $10.03M to -$6.71M.